Aspen Pharmacare Holdings Limited · JSE:APN

Aspen Pharmacare — FY2018 Earnings Presentation

52 slides from Aspen Pharmacare's earnings presentation, September 2018

  1. Slide 1: Annual Results Presentation

    Healthcare. We Care. Annual Results Presentation For the year ended 30 June 2018

  2. Slide 2: Table of Contents

    TABLE OF CONTENTS Stephen Saad Group Chief Executive Major Global Transactions Review Performance Review Gus Attridge Deputy Group Chief Executive Financial Review Stephen Saad Summary & Prospects Appendices

  3. Slide 3: Financial Highlights

    FINANCIAL HIGHLIGHTS 3 Revenue R42.6bn 3% (5% CER) EBITDA R12.0bn 5% HEPS 1 469 cps 13% (14% CER) NHEPS 1 605 cps 10% • Currency – major factor - H2 > H1 revenue in CER • 105% cash conversion • Solid performance in commercial pharma sustained +8% (CER) - China leading performer • Challenges in manuf

  4. Slide 4: Our Current GPS

    OUR CURRENT GPS 4 • Aspen is a global multinational • Leading global and regional positions - Critical mass and economies of scale enhance returns - No 1 in anaesthetics (excluding USA) - No 2 in injectable anticoagulants (excluding USA) - Leading global producer of regulated steroidal/hormonal APIs

  5. Slide 5: Globally Unique Business Model

    GLOBALLY UNIQUE BUSINESS MODEL 5 • Only truly global multinational pharma company based in an EM - Only multinational pharma company weighted to EM • Resilient to future healthcare pressures - Scale and diversity of global IP - Breadth of geographic presence - Limited exposure to generic commoditisa

  6. Slide 6: 20 Years of Sustained NHEPS Growth

    20 YEARS OF SUSTAINED NHEPS GROWTH 6 FY 1999 – FY 2013 FY 2014 – FY 2018 From humble beginnings to regional leadership From regional leadership to global therapeutic leadership 1 605 1 463 1 264 1 146 1 064 CAGR +26% 837 660 555 487 389 Cents 210 231 138 185 63 79 104 20 34 46 FY 1999 FY 2000 FY 200

  7. Slide 7: 20 Year Review

    20 YEAR REVIEW 7 FY 1999 – FY 2013 • Regional Leadership • Demonstrated we are industrialists not financiers - South Africa: ~ 1 in 4 scripts dispensed - Invest in strategic capex - Australia: ~ 1 in 5 scripts written - Change trajectory of products acquired • Important lessons learned • Alert to ch

  8. Slide 8: Major Global Transactions Review

    MAJOR GLOBAL TRANSACTIONS REVIEW 8 FY 1999 – FY 2012 • Key regional transactions included INITIAL GSK GLOBAL TRANSACTIONS - FY 1999: Acquisition of South African Druggists Acquired Sales - FY 2010: Formation of SSA Collaboration with GSK R’bn Consideration % change Sales FY 2018 - FY 2011: Addition

  9. Slide 9: Major Global Transactions Review (continued)

    MAJOR GLOBAL TRANSACTIONS REVIEW (continued) 9 Thrombosis transactions Acquired Sales FY • Aspen has completed five thrombosis transactions R’bn Consideration % change Sales 2018 - GSK Thrombosis Business  FY 2014: Acquired products, manufacturing FY 2014 GSK Thrombosis 8.77(a) 4.89 business and st

  10. Slide 10: Major Global Transactions Review (continued)

    MAJOR GLOBAL TRANSACTIONS REVIEW (continued) 10 MSD Transactions • MSD Business(1) R’bn Consideration(a) Acquired Sales Sales FY 2018 % change - FY 2014: Acquired API facility (Oss), products(2) and working capital from MSD MSD Business 6.69 5.04 6.15 22% - Provided steroidal, hormonal, peptide and

  11. Slide 11: Major Global Transactions Review (continued)

    MAJOR GLOBAL TRANSACTIONS REVIEW (continued) 11 The IMF Transactions • FY 2013: Acquired Nestlé's infant nutritionals portfolio for R’bn Consideration Acquired Sales Sales FY 2018 % change distribution in Australia & certain Southern African* territories • FY 2014: Acquired additional territorial ri

  12. Slide 12: Performance Review

    Performance Review HoLDING S

  13. Slide 13: Group Revenue

    GROUP REVENUE 13 R’m FY 2018 FY 2017 % change FY 2017 (CER)* % change Commercial Pharma 33 270 31 437 6% 30 947 8% - Anaesthetics 8 332 7 065 18% 6 906 21% - Thrombosis 6 430 5 665 14% 5 753 12% - High Potency & Cytotoxics 4 172 4 687 -11% 4 596 -9% - Regional Brands 14 336 14 020 2% 13 692 5% Nutri

  14. Slide 14: Commercial Pharma Revenue Contribution by Region & Therapeutic Category

    COMMERCIAL PHARMA REVENUE CONTRIBUTION | BY REGION & THERAPEUTIC CATEGORY 14 Total Commercial Pharma Revenue +8% -11% R33.3bn 56% EM Revenue Contribution +12% +21% +5% ROW R2.3bn 7% Asia Pacific Anaesthetics R4.2bn R8.3bn 13% 25% DEVELOPING EUROPE & RUSSIA/CIS DEVELOPED USA & SSA CANADA EUROPE R7.9b

  15. Slide 15: Anaesthetics

    ANAESTHETICS 15 FY 2018 FY 2017 (CER) % change • DM +16% R’m - ~ 40% of DM sales from Japan and Australia Developed Markets 4 435 3 831 16% - Japan – pricing pressure/volume growth • EM +27% Emerging Markets 3 897 3 075 27% - Positive performance in Latam, Asia Pacific & Developing EU Total Revenue

  16. Slide 16: Thrombosis

    THROMBOSIS 16 R’m FY 2018 FY 2017 (CER) % change • DM +7% - ~ 80% of sales Developed Markets 3 549 3 302 7%  Germany/France/Italy Emerging Markets 2 881 2 451 18% - Solid performance across the board sustained Total Revenue 6 430 5 753 12% - Outperformed European peers • EM +18% 45% EM Revenue Cont

  17. Slide 17: High Potency & Cytotoxics

    HIGH POTENCY & CYTOTOXICS 17 R’m FY 2018 FY 2017 (CER) % change • DM -10% - Performance impacted by USA ( sales decline of ~ R150m) Developed Markets 2 407 2 673 -10%  Pack size change Emerging Markets 1 765 1 923 -8% - Developed Europe affected by increased generic pressure Total Revenue 4 172 4 5

  18. Slide 18: Regional Brands

    REGIONAL BRANDS 18 R’m FY 2018 FY 2017 (CER) % change • Underlying growth Emerging Markets 9 938 9 048 10% - Total regional brands sales +8% - SSA 7 876 7 123 11% - DM sales +5% - EM: Rest of World 2 062 1 925 7%  HPC impacts Rest of DM Developed Markets 4 398 4 644 -5% • South Africa sales of R7 1

  19. Slide 19: Manufacturing & Operations

    MANUFACTURING & OPERATIONS 19 R’m FY 2018 FY 2017 (CER) % change API 4 591 4 480 2% FDF 1 644 2 100 -22% Total Revenue 6 235 6 580 -5% Performance Prospects • Good API sales performance • API stable aside from Heparin - H2 in line with H1 - Pricing pressure - Facility closures impacted recovery/cost

  20. Slide 20: Impact on Currency H2 2018 vs H1 2018

    IMPACT ON CURRENCY H2 2018 vs H1 2018 20 • Rand sales decrease of R1.3bn H1 2018 H2 2018 - Almost all commercial pharma EUR 15.77 14.88 - However in CER  H2 2018 > H1 2018 AUD 10.45 9.48 • Commercial pharma performance metrics H2 2018 vs H1 2018 CNY 2.02 1.93 - Excluding anaesthetics +2% USD 13.41

  21. Slide 21: Commercial Pharma Internal Organic Sales Growth Measure

    COMMERCIAL PHARMA | INTERNAL ORGANIC SALES GROWTH MEASURE 21 Total Commercial Pharma +7.5% Adjusted for Anaesthetics -3.7% Adjusted for: +0.7% ↓ Acquisitions – China (Thrombosis)/Latam ↑ HPC and Divestments in SSA/Latam Base Organic Growth +4.5% DEMONSTRATION OF CHANGED TRAJECTORY PROFILE OF PRODUCT

  22. Slide 22: Financial Review

    Financial Review HoLDING S

  23. Slide 23: Abridged Statement of Normalised Comprehensive Income

    ABRIDGED STATEMENT OF NORMALISED COMPREHENSIVE INCOME 23 FY 2017 R’m FY 2018 FY 2017 % change % change (CER)* Net revenue 42 596 41 213 3% 40 690 5% Gross profit 21 605 19 896 9% 19 777 9% Gross profit margin 50.7% 48.3% 48.6% Operating expenses (10 563) (9 500) 11% (9 374) 13% Net other operating i

  24. Slide 24: Currency Impact FY 2018

    CURRENCY IMPACT | FY 2018 24 Revenue 27% • Most relevant currencies affecting earnings - EUR, ZAR, AUD 22% 20% - CNY, JPY - USD 13% 7% Reported CER 6% 5% Revenue 3% 5% Normalised EBITDA 5% 5% EUR ZAR AUD USD CNY JPY Other NHEPS 10% 10% EXCHANGE RATE VARIATION ALWAYS A FACTOR TO CONSIDER

  25. Slide 25: Impact of Exchange Rate Movements

    IMPACT OF EXCHANGE RATE MOVEMENTS 25 ZAR movement: June 2017 – August 2018 (based to 100) 120.0 115.0 110.0 105.0 100.0 95.0 90.0 85.0 80.0 30-Jun-17 30-Jul-17 29-Aug-17 28-Sep-17 28-Oct-17 27-Nov-17 27-Dec-17 26-Jan-18 25-Feb-18 27-Mar-18 26-Apr-18 26-May-18 25-Jun-18 25-Jul-18 24-Aug-18 USD EUR AU

  26. Slide 26: EBITDA Margin

    EBITDA MARGIN 26 Contribution to change in Normalised EBITDA Margin +0,5% +0,5% -1.4% -1.4% -0.2% 4.0% -1.2% -1.4% -0.5% 28,2% -0.2% 27.7% Change in Gross Profit -0.9% Net Opex 2,4% -1.9% FY 2017 Therapeutic Other Nutritionals Selling & Administrative Net other FY 2018 Normalised focused brands phar

  27. Slide 27: Reconciliation of NHEPS

    RECONCILIATION OF NHEPS 27 Cents FY 2018 FY 2017 % change Basic earnings per share (EPS) 1 316.6 1 123.4 17% Net impairments 151.5 136.7 Loss on sale of assets 0.7 39.4 Headline earnings per share (HEPS) 1 468.8 1 299.5 13% Capital raising fees 44.4 23.4 Restructuring costs 27.5 66.7 Transactions co

  28. Slide 28: Net Funding Costs

    NET FUNDING COSTS 28 R’m FY 2018 FY 2017 % change Net interest paid (1 541) (1 531) 1% Foreign exchange losses (16) (200) Forward exchange contracts gains/(losses) 104 (37) Notional interest on financial instruments (408) (339) Normalised net funding costs (1 861) (2 107) -12% Debt raising fees on a

  29. Slide 29: PPE Capital Expenditure

    PPE CAPITAL EXPENDITURE 29 • Major projects underway to enable Aspen to manufacture PPE Capex - R'm anaesthetics 3000 2 800 - Port Elizabeth - steriles 2500 - Notre Dame de Bondeville – blow-fill seal 2 145 - Bad Oldesloe – creams, gels, liquids 2000 1 741 1 593 1 484 1500 1 329 1000 500 0 FY 2014 F

  30. Slide 30: Working Capital and Cash Flow

    WORKING CAPITAL AND CASH FLOW 30 R’m FY 2018 FY 2017 Net Working capital • Working capital as % of revenue impacted by material difference 18 157 16 716 between average and closing exchange rates Net Working capital – excluding Oss -1,495 13 511 12 465 − -1,816excluding Oss) At average rate = 41% (3

  31. Slide 31: Borrowings

    BORROWINGS 31 Blended NACQ interest rates for borrowings as at 30 June 2018 R’m FY 2018 FY 2017 Debt denomination Weighted average rate p.a Opening balance 37 131 32 694 ZAR 8.47% Cash flow from operating activities (7 017) (6 487) AUD 4.26% Capital expenditure - PPE 2 145 1 484 EUR 1.81% Acquisitio

  32. Slide 32: Borrowings

    BORROWINGS 32 • Analysis of R46.8 bn net borrowings 37.1 Net borrowings 46.8 10.7 Cash 11.2 18.9 Current 11.2 29.0 Non-current 46.7 2017 2018 SUCCESSFUL AMEND AND EXTEND OF SYNDICATED FACILITIES WITH 28 LENDERS ANNOUNCED IN MAY 2018

  33. Slide 33: Disposal of Global Nutritionals Business

    DISPOSAL OF GLOBAL NUTRITIONALS BUSINESS 33 • Significant response - Over 50 expressions of interest - Both regionally and/or globally - Compelling offers at both regional and global levels - Aspen had options • Lactalis offer was accepted on balance of factors because it represented: - Value - Best

  34. Slide 34: H2 Performance

    H2 PERFORMANCE 34 What we said What we delivered • “The sales achieved in the first half of the 2018 financial year are • H2 sales marginally above H1 sales (CER). expected to be maintained in the second half.” • “Emerging Markets should continue to be the most important • Emerging Market growth ahe

  35. Slide 35: Summary & Prospects

    Summary & Prospects HoLDING S

  36. Slide 36: Prospects | Pipeline

    PROSPECTS | PIPELINE 36 High Potency - USA Anaesthetics - China • Esterified estrogens – launched • EMLA/Nimbex shelf life resolved • Conjugated estrogens • Launch end of 2019 - Trial batches September 2018 - Stability submission June 2019 Regional Brands - Launch end 2019 • HPC – two pronged approa

  37. Slide 37: Prospects | Commercial Pharma

    PROSPECTS | COMMERCIAL PHARMA 37 Developed Markets – Focus Brands Emerging Markets – Focus Brands • Thrombosis – strong year • Growth across all categories - Growth off this base - High Potency supply/regulatory dependent • High Potency • China catalyst for growth - ~ EUR20m of sales under pressure

  38. Slide 38: Prospects | Value Creation - Trend Correction

    PROSPECTS | VALUE CREATION - TREND CORRECTION 38 Anaesthetics Portfolio Arixtra & Fraxiparine Pre-acquisition Post-acquisition Pre-acquisition Post-acquisition GSK (GBP) sales declined 17% Aspen ZAR sales grew 8% GSK & AZ (USD) combined sales Aspen ZAR sales grew 2% declined 33% -17% -33% 480 +2% 46

  39. Slide 39: Prospects | Value Creation – Growth Through EM

    PROSPECTS | VALUE CREATION – GROWTH THROUGH EM 39 Emerging Market contribution per therapeutic category Sales Growth DM EM 69% 66% 21% Anaesthetics 16% 27% 56% 3% Other Focus Brands -1% 7% 52% 45% 45% 8% Regional Brands* 5% 10% 43% 42% 37% 8% Commercial Pharma 2% 12% 34% *Excluding HPC, divestments/

  40. Slide 40: Prospects | Infant Milk Formulas | Value Creation

    PROSPECTS | INFANT MILK FORMULAS | VALUE CREATION 40 • Early set back – loss R730m in Venezuela Asia Pacific - Grew balance of acquired Nestlé sales +37% • Successfully transitioning brand in Australia • Key enhancements created • China opportunity, the needle mover - Fundamentals and material value

  41. Slide 41: Prospects | Transactions Summary

    PROSPECTS | TRANSACTIONS SUMMARY 41 R’bn • Acquiring global brands is expensive - Returns not always immediately apparent GSK Thrombosis Portfolio 8.77 • Consistent performance needed to enhance value MSD business 6.69 • Using any measure we have performed on these transactions Nestlé & other IMF tr

  42. Slide 42: Prospects | Summary

    PROSPECTS | SUMMARY 42 • Stabilised commercial pharma base - Consistent and predictable • EM continue to drive growth - China a catalyst • Synergies - Further volumes • Manufacturing business headwinds  NDB – Thrombosis • DM  Mono Embolex transfer - High Potency a continued challenge - USA pipelin

  43. Slide 43: Prospects | Summary Continued

    PROSPECTS | SUMMARY CONTINUED 43 • Currency - Relative ZAR performance - Major factor for Aspen • Reversal of declining trends acquired - Sustainable - Demonstration of capabilities - Settled large strategic transactions - Value creation • Full appreciation of current business and relative prospects

  44. Slide 44: Reflections on Lessons Learned Over 20 Years

    REFLECTIONS ON LESSONS LEARNED OVER 20 YEARS 44 • Doing something worthwhile makes life rewarding • Busy people contributing positively to others lives are invariably happy - Sustainable business transcends profit alone people - Central to the Aspen journey has been and is creating patient • Managem

  45. Slide 45: Disclaimer

    DISCLAIMER 45 CAUTIONARY REGARDING FORWARD-LOOKING STATEMENTS This presentation has been prepared by Aspen Pharmacare Holdings Limited based on information available to it as at the date of the presentation. This presentation may contain prospects, projections, future plans and expectations, strateg

  46. Slide 46: Appendices

    APPENDICES Appendix 1: Abridged Group statement of comprehensive income Appendix 2: Group statement of financial position Appendix 3: Extract from Group statement of cash flows Appendix 4: Group revenue by region Appendix 5: Institutional investors

  47. Slide 47: Appendix 1: Abridged Group Statement of Comprehensive Income

    APPENDIX 1: ABRIDGED GROUP STATEMENT OF COMPREHENSIVE INCOME 47 R’m FY 2018 FY 2017 % change Net revenue 42 595 41 213 3% Cost of sales (20 991) (21 317) -2% Gross profit 21 605 19 896 9% Gross profit margin 50.7% 48.3% EBITDA 10 609 9 588 11% EBITDA margin 24.9% 23.3% Depreciation (740) (700) 6% Am

  48. Slide 48: Appendix 2: Group Statement of Financial Position

    APPENDIX 2: GROUP STATEMENT OF FINANCIAL POSITION 48 R'm FY 2018 FY 2017 TOTAL ASSETS Non-current assets 92 614 78 230 Intangible assets 72 163 60 006 Property, plant and equipment 11 368 9 749 Goodwill 6 126 5 940 Deferred tax assets 966 987 Contingent environmental indemnification assets 802 747 O

  49. Slide 49: Appendix 2: Group Statement of Financial Position (continued)

    APPENDIX 2: GROUP STATEMENT OF FINANCIAL POSITION (CONTINUED) 49 R‘m FY 2018 FY 2017 EQUITY AND LIABILIITIES Share capital and reserves 50 095 43 138 Non-current liabilities 54 369 38 396 Borrowings 46 725 28 978 Other non-current liabilities 2 524 4 381 Unfavourable and onerous contracts 1 382 1 63

  50. Slide 50: Appendix 3: Extract from Group Statement of Cash Flows

    APPENDIX 3: EXTRACT FROM GROUP STATEMENT OF CASH FLOWS 50 R'm FY 2018 FY 2017 % change Cash operating profit 11 907 10 817 10% Changes in working capital (1 579) (915) 73% Cash generated from operations 10 328 9 902 4% Net finance costs paid (1 816) (1 913) -5% Tax paid (1 495) (1 502) 0% Cash gener

  51. Slide 51: Appendix 4: Group Revenue by Region

    APPENDIX 4: GROUP REVENUE BY REGION 51 FY 2017 R’m FY 2018 FY 2017 % change % change (CER)* Developed Europe 12 329 11 431 8% 11 871 4% Sub-Saharan Africa 10 008 9 892 1% 9 571 5% Asia Pacific 11 806 10 957 8% 10 596 11% Latin America 4 231 4 184 1% 3 991 6% Developing Europe and CIS 2 780 2 589 7%

  52. Slide 52: Appendix 5: Institutional Investors

    APPENDIX 5: INSTITUTIONAL INVESTORS 52 Asia Pacific ROW 3% 7% Europe 4% UK 4% North America 18% South Africa 64% As at 29 June 2018

Aspen Pharmacare Holdings — FY2018 Earnings Presentation on 6ix